Table 1 MDS patient characteristics of the material used for in vitro experiments
Patient ID | WHO 2016 | IPSS | Agerange | Sex | Karyotype | Tracking lesions |
|---|---|---|---|---|---|---|
P01 | MDS-MLD | low | 60–65 | m | 46,XY[20] | TET2 |
P02 | MDS-EB1 | int-1 | 60–65 | m | 46,XY[20] | SF3B1 |
P03 | MDS-MLD | int-2 | 70–75 | m | 46,XY[20] | Not detected |
P04 | MDS-EB1 | int-2 | 60–65 | m | 46,XY, + 1.der(1;16)(q10;p10)[18/20] | RUNX1, IDH1, IDH2, SRSF2 |
P05 | MDS-EB2 | high | 60–65 | m | 45,X, -Y [11]; 45,X,-Y,del(9)(q21q32) [5]; 45,X,-Y,del(9)(q13q34)[4] | KRAS |
P06 | MDS-EB2 | int-2 | 40–45 | f | 45,XX,-7[15] | IDH2 |
P07 | MDS-MLD | int-1 | 70–75 | m | 46,XY[20] | Not detected |
P08 | MDS-RS-MLD | low | 70–75 | m | 46,XY[20] | SF3B1 |
P09 | MDS-MLD | int-1 | 80–85 | m | 46,XY[20] | Not detected |
P10 | MDS-MLD | int-1 | 80–85 | f | 46, XX[25] | ASXL1, DNMT3A |
P11 | MDS-EB1 | int-1 | 55–60 | f | 46,XX[20] | TP53, SF3B1 |
P04_2 | MDS-EB1 | int-2 | 60–65 | m | 46,XY, + 1.der(1;16)(q10;p10)[18/20] | RUNX1, IDH1, IDH2, SRSF2 |